Vericel Corp — Capital/Financing Update 2014

Sep 11, 2014

8-K 1 a14-18419_88k.htm 8-K

*UNITED STATES SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of*

*The Securities Exchange Act of 1934*

Date of Report (Date of Earliest Event Reported): September 11, 2014

*Aastrom Biosciences, Inc.*

(Exact name of registrant as specified in its charter)

Michigan	000-22025	94-3096597
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

24 Frank Lloyd Wright Drive, Lobby K, Ann Arbor, Michigan	48105
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (800) 556-0311

*Not Applicable*

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108739\14-18419-8\task6970574\18419-8-ba.htm',USER='108739',CD='Sep 11 17:35 2014'

*Item 8.01. Other Events.*

On September 11, 2014, Aastrom Biosciences, Inc. (the “Company”) issued a press release announcing the pricing of an underwritten public offering. The Company agreed to offer and sell 13,725,490 shares of its common stock, no par value per share, at a public offering price of $2.55 per share, less underwriting discounts and commissions payable by the Company. The Company expects to receive approximately $35,000,000 in gross proceeds from the offering before underwriting discounts and commissions and other estimated offering expenses.

The Company has also granted to the underwriters a 30-day option to purchase up to an additional 2,058,823 shares of its common stock to cover over-allotments, if any.

A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

*Item 9.01. Financial Statements and Exhibits.*

Exhibit 99.1 Press release of Aastrom Biosciences, Inc., dated September 11, 2014.

1

SEQ.=1,FOLIO='1',FILE='C:\JMS\108739\14-18419-8\task6970574\18419-8-ba.htm',USER='108739',CD='Sep 11 17:35 2014'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 11, 2014
By:	/s/ Gerard Michel
Name:	Gerard Michel
Title:	Chief Financial Officer and Vice President, Corporate
Development

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108739\14-18419-8\task6970574\18419-8-ba.htm',USER='108739',CD='Sep 11 17:35 2014'